OncoTherapy Science, Inc. (TYO:4564)
Japan · Delayed Price · Currency is JPY 29.00
-1.00 (-3.45%)
Jul 31, 2025, 3:30 PM JST
Lumos Pharma Revenue
In the fiscal year ending March 31, 2025, OncoTherapy Science had annual revenue of 750.00M JPY with 22.95% growth. OncoTherapy Science had revenue of 187.00M in the quarter ending March 31, 2025, with 29.86% growth.
Revenue
750.00M
Revenue Growth
+22.95%
P/S Ratio
10.74
Revenue / Employee
15.96M
Employees
47
Market Cap
8.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 750.00M | 140.00M | 22.95% |
| Mar 31, 2024 | 610.00M | -524.00M | -46.21% |
| Mar 31, 2023 | 1.13B | -19.00M | -1.65% |
| Mar 31, 2022 | 1.15B | 821.00M | 247.29% |
| Mar 31, 2021 | 332.00M | 16.00M | 5.06% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.22B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 866.03B |
| Takeda Pharmaceutical Company | 4,480.25B |
| Otsuka Holdings | 2,393.18B |
| Terumo | 1,036.17B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |